Scrip Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company hopes to follow on from Keytruda's success after Merck's drug won a groundbreaking FDA approval last year based on biomarkers rather than tumor location.
08.02.2018
NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology
More news
16.12.2024
Neophore appoints Michael Shih as Chief Executive Officer
NeoPhore appoints Michael Shih as Chief Executive Officer • Highly experienced corporate development leader with a track record of international p…
22.05.2024
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore…
11.04.2024
NeoPhore presented preclinical data from our PMS2 program at the AACR Annual Meeting, San Diego, 5 - 10 April 2024.
The NeoPhore team attended the American Association for Cancer Research Annual Meeting in San Diego, 5 - 10 April 2024. In collaboration with The…